D
efense mechanisms against the detrimental effects of peritonitis are critically important to the integrity of the peritoneal membrane, especially in peritoneal dialysis (PD). In PD patients it has been shown that the peritoneum is damaged by the process of PD itself and further during bouts of peritonitis (1) . The defensin system could be of particular significance in the defense against PD-associated peritonitis (2) . In this respect, a wide variety of proteins and peptides play a role in the local innate defense systems of mammals.
Defensins comprise a class of cationic antimicrobial peptides with a molecular weight of 3 -5 kDa and are conserved throughout phylogeny (3) (4) (5) (6) (7) . In humans the genes encoding for defensins are located on chromosome 8 (5, 6) . The genomic organization suggests one ancestral gene that has been duplicated throughout evolution (8) . The position of three intramolecular disulfide bonds allows differentiation of the α-from the β-defensins (9) . So far, 6 α-defensins and 4 β-defensins have been identified in humans. The α-defensins comprise human neutrophil peptides 1 -4 (HNP1-4), abundant in granu- Figure 2 ). The following controls were used to ensure specificity of the staining reaction: (1) omission of the primary antibody; (2) omission of the biotinlabeled secondary antibody; (3) omission of the streptavidin-biotin complex; (4) omission of the primary antibody, the biotin-labeled secondary antibody, and the streptavidin-biotin complex; (5) omission of the primary antibody and the biotin-labeled secondary antibody; (6) omission of the biotin-labeled secondary antibody and the streptavidin-biotin complex; (7) omission of the primary antibody and the streptavidin-biotin complex;
locytes, and human defensins 5 and 6, originally detected in Paneth cells (10, 11) . The human β-defensins (HBD) are of epithelial origin and are found in the skin, intestine, and lung (8, 12, 13) . Defensins have a broad spectrum against various bacteria. The aim of this study was to evaluate the expression of defensins in the peritoneum of healthy controls compared with patients with pathological changes of the peritoneum.
MATERIALS AND METHODS
Peritoneal tissue was obtained during routine surgery. All patients gave formal consent and the local ethics board approved the study. The chart reviews were done retrospectively.
There were two parts (A/B) to the analysis: In Part A, expression of different defensins, as determined by mRNA and immunohistochemistry in peritoneal biopsies from 12 patients without any pathological signs of damage, 5 patients with signs of peritoneal inflammation with normal kidney function, and 4 patients with histologically proven cancer of the peritoneum (peritoneal metastasis), and cultured human peritoneal mesothelial cells, was analyzed. In Part B, we investigated biopsies from different subgroups based on pathological examination: 25 patients without any signs of inflammation (biopsy gained during herniotomy), 35 patients with appendicitis (25 with chronic and 10 with acute appendicitis based on pathological examination), and 25 with end-stage renal disease (ESRD). For the ESRD patients, biopsies were taken at the time of insertion of the PD catheter (n = 15) or, for patients on PD, during routine surgery (n = 10). The PD patients commenced dialysis up to the day before surgery.
TISSUE PROCESSING
One fraction of the tissue was deep-frozen [either native or incubated for 1 day in RNAlater (Qiagen, Hilden, Germany) prior to freezing] and another fraction was fixed in formalin for 24 -48 hours and embedded in paraffin. After the paraffin blocks were cut into 3-µm slices, standard staining procedures (hematoxylin and eosin, iron, and Mason-Goldner) were performed. In addition, immunohistochemical staining for defensins was performed.
IMMUNOHISTOCHEMICAL STAINING
Immunohistochemical staining was performed using the EnVision kit K5007 (DakoCytomation, Hamburg, Ger- 
EVALUATION OF IMMUNOHISTOCHEMISTRY
Two experienced investigators initially evaluated the slides (using light microscopy) to determine the frequency and intensity of immunohistochemical staining. Qualitative staining of both the cytoplasm and the nucleus of mesothelial cells were recorded separately as "no" (0), "weak" (1), "moderate" (2), or "intense" (3) if more than 10% of cells were stained. The investigators were blinded regarding clinical diagnosis. The scores were added together to give the immunoreactive score, which ranged from 0 to 6. In addition, the staining results obtained for the submesothelial layer were graded for vessels (0 -3), connective tissue (0 -3), and fatty tissue (0 -3). In the case of infiltration by inflammatory cells, the staining of these cells was also graded as "no" (0), "weak" (1), "moderate" (2), or "intense" staining (3). Therefore, for the submesothelial layer, a maximum score of 12 was attainable.
ISOLATION AND CULTURE OF MESOTHELIAL CELLS
Mesothelial cells were detached from the tissue using trypsin/EDTA. Cells were centrifuged for 5 minutes at 800 rpm and the pellet resuspended in HAM's F12 medium supplemented with 100 U/mL penicillin, 100 U/mL streptomycin, 2 mmol/L glutamine, 2.5 µg/mL amphotericin B, and 10% fetal calf serum. Approximately 10 6 cells/well were seeded onto a 6-well tissue culture plate (962 mm 2 /well) with 2 -3 mL HAM's F12 medium. The culture plate was precoated with a 0.1% gelatin solution. Cells were incubated in 5% CO 2 at 37°C ; on the following day the medium was replaced to remove the blood cells. The medium was then replaced every 2 -3 days until confluence, whereupon the cells were detached with trypsin/EDTA and seeded into a 7.5-cm 2 flask. At each passage the cells were split 1:10. The first passage was named P0, the following P1, etc.; cells were cultivated mostly to P3 or P4.
ISOLATION OF RNA
RNA from cultured cells was isolated using TRIzol Reagent (Invitrogen, San Diego, California, USA) according to the supplier's protocol. The quality and quantity of RNA were determined by photometry. RNA from deepfrozen tissues was extracted using the RNeasy Lipid Tissue Mini Kit (Qiagen).
SYNTHESIS OF CDNA
The AMV-Reverse Transcriptase Kit (Promega, Mannheim, Germany) was used according to the supplier's instructions. Total RNA (1 µg) was reverse transcribed with oligo (dT) primers. The reaction volume was made up to 100 µL with nuclease-free water.
ANALYSIS OF DEFENSIN EXPRESSION
Analyses of mRNA defensin expression were performed in a fluorescence temperature cycler (LightCycler, Roche Diagnostics GmbH, Mannheim, Germany). cDNA (1 µL) was amplified in a reaction mixture containing 3 mmol/L MgCl 2 , 0.5 µmol/L (each) primer, and 1x LightCycler-FastStart DNA Master SYBR Green I mix (Roche Diagnostics). Initial denaturation at 95°C for 10 minutes was followed by 45 cycles, each cycle consisting of 95°C for 10 seconds, the oligo-specific annealing temperature for 5 seconds, and 72°C for 15 seconds. For HBD1 (sense: 5'-TTGTCTGAGATGGCCTCAGGTGGTAAC-3'; antisense: 5'-ATACTTCAAAAGCAATTTTCCTTTAT-3') and HBD2 (sense: 5'-ATCAGCCATGAGGGTCTT GT-3'; antisense: 5'-GAGACCACAGGTGCCAATTT-3'), the annealing temperature was 60°C. For HBD3 (sense: 5'-AGCCTAGCAGCTATG AGGATC-3'; antisense: 5'-CTTCGGCAGCATTTTCGGCCA-3'), a touchdown protocol with a primary temperature of 66°C and a target temperature of 60°C was used. For HNP1 (sense: 5'-GACCCCAGCCATGAGGAC-3'; antisense: 5'-ATTCTGCAATAGCAGGCC-3') and HNP3 (sense: 5'-GAC CCCAGCCATGAGGAC-3'; antisense: 5'-ATTCTGCAATAG CAGTCC-3'), the annealing temperature was 56°C. At the end of each run, melting curve profiles were produced by cooling the samples to 65°C for 15 seconds and heating slowly (0.2°C/second) to 95°C (HNP1 and HNP3: 99°C), with continuous measurements of fluorescence to confirm amplification of specific transcripts. Cycleto-cycle fluorescence emission readings were monitored and analyzed with LightCycler software (Roche Diagnostics). Standard curves were obtained for each primer set by serial dilutions of a standard control (each run contained a standard control with a known concentration) and, on this basis, cDNA concentration could be quantified.
STATISTICS
All results were evaluated using ANOVA and for post tests, the Bonferroni method, Dunett's test, or t-tests were used (Prism, GraphPad Software, San Diego, California, USA).
RESULTS

PART A
mRNA Expression: The patients' characteristics are given in Table 1 . HNP1, HNP3, HBD1, HBD2, and HBD3 mRNA were detected in the peritoneum (Figure 3) . Throughout the different subgroups, HBD1 was expressed in a similarly intense fashion. Expression of HBD2 and HBD3 was more prominent in patients with peritoneal inflammation.
Protein Expression: Comparison of the results from the two independent observers showed a kappa value of 0.83. In the tissue slides, HNP1,3 and HBD1 were detectable, while HBD2 was not (Figure 4 ).
Comparing mRNA and Protein Expression: We compared the results of the mRNA and immunohistochemistry measurements for HNP1, HBD1, and HBD2 in the 12 normal peritoneal tissue slides. In slides without detection of defensins by mRNA, we were also not able to find defensins by immunohistochemistry. In addition, the implemented positive and negative controls were all specific [not shown; for details, see Ref. (14)].
PART B: EXPRESSION OF DEFENSINS IN DIFFERENT PATIENT GROUPS
Quantitative dif ferences in the expression of defensins were assessed between the different patient groups, with particular regard to the PD patients. The clinical data are given in Table 2 . HNP1,3 were strongly expressed in vessels and leukocytes that infiltrated the peritoneum and this was most pronounced in those patients with acute appendicitis [ Figure 5 (a); Table 3 ]. However, the mesothelial cells containing HNP1,3 showed markedly decreased expression in ESRD and PD patients [ Figure 6 (a); Table 3 
DISCUSSION
This study is the first systematic exploration of expression patterns of peritoneal defensins as a part of the innate immune system in the normal and damaged peritoneum, the latter caused by different etiologies.
We detected HNP1, HNP3, HBD1, HBD2, and HBD3 in the peritoneum. HBD1 was expressed in mesothelium in a seemingly constitutive manner, as reported by other groups, in different regions of the body; in the submesothelial there was downregulation in a chronic inflammatory state (11, (15) (16) (17) (18) (19) . HBD2 was previously found by Zarrinkalam and co-workers in the peritoneum of 8 PD patients; however, they did not study all the other defensins (20) . They concluded that HBD2 is the most abundantly expressed and important defensin in the peritoneum. In our investigations, expression of HBD2 was minor compared with that of the other defensins in all examined tissues (normal and inflamed peritoneum, as well as in the peritoneum of ESRD patients), and there was a nonsignif icant trend to HBD2 induction in peritoneum of patients with appendicitis. These findings could be explained by defensin-activating mechanisms. Defensins are activated by a direct response to bacterial components mediated by signaling pathways involving Toll-like receptors, and by cytokine-driven induction (e.g., by interleukin-1β and tumor necrosis factor-α) (15, 21) . It has previously been shown that NOD2 serves as an intracellular pattern recognition receptor and causes induction of HBD2 (22) .
Our special interest was the expression of defensins in ESRD and especially in PD patients. The present study showed decreased expression of HNP1,3 (mesothelial and submesothelial) in these patients. In contrast to this observation, we found upregulation of HNP1,3 (mesothelial and submesothelial) in patients with pathologically proven acute appendicitis. On first glance it is somewhat surprising to find decreased HNP1,3 in ESRD patients, since these patients are in a state of microinflammation and, in the case of PD, the local effects of the PD fluids on the peritoneum should contribute addi- tionally to a proinflammatory state (23) . However, we have previously found impairment of other constituents of the innate immune system caused by PD fluids (24) . Therefore, one could speculate that a defensin insufficiency may be a result of the side effects of PD fluids and the well-established reduced mesothelial cell count in PD patients. There is increasing interest in detecting the mechanisms involved in peritoneal membrane failure; for example, the role of epithelial-to-mesenchymal transition, the role of peritoneal fibrosis, and the role of the submesothelial layer. A complex pathophysiological network has been described (25) , but the role of the defensin system in this context is not understood. However, patients with ESRD who had never been exposed to PD fluids also displayed a reduced defensin expression, indicating that uremia per se may be a causative factor. This is in line with the well-known dysregulation of the innate immune system in advanced chronic kidney disease (26) .
In conclusion, we were able to demonstrate the expression of several defensins in the peritoneum. We found that HBD1 is constitutively expressed in the mesothelium, while HBD2 is potentially induced by inflammation and HNP1,3 are upregulated during an acute inflammatory process. In addition, we observed a decreased expression of defensins (HNP1,3) in the peritoneum of ESRD and PD patients, which could be important with respect to PD-associated infective complications.
